Esther Bommer
Schlieren, ZH 8952, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.
Journal: Cancer research communications
Published: March 18, 2026
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB.
Journal: Antibodies (Basel, Switzerland)
Published: September 27, 2025
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.
Journal: Blood
Published: February 20, 2025
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.
Journal: Nature
Published: March 14, 2021
Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Journal: Frontiers in oncology
Published: January 06, 2021
Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 09, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026